Lijun International (HKG:2005) Subsidiary Shijiazhuang No.4 Pharma Successfully Developed Enerxin Capsule, An Effective Restraint Of The Growth Of Influenza A (H1N1)

Hong Kong, Nov 9, 2009 AEST (ABN Newswire) - Lijun International Pharmaceutical (Holding) Co., Ltd. (HKG:2005) and its subsidiary (the "Group") are pleased to announce that Enerxin Capsule, which is developed and researched by Shijiazhuang No.4 Pharmaceutical Co., Ltd. ("Shijiazhuang No.4 Pharma"), a wholly-owned subsidiary of the Company, has been recognized by the State Key Laboratory of Virology for effective restraint of the growth of Influenza A (H1N1) on 31 October 2009.

Enerxin Capsule (generic name: Arbidol Hydrochloride Capsule) is a new antiviral drug developed and researched by Shijiazhuang No.4 Pharma and is a State Class II Prescription New Drug, and was granted National New Drug Certificate and Production Permit in October 2004. After a total of more than 200 clinical trials to this medicine conducted by Beijing Union Medical College Hospital, China-Japan Friendship Hospital and General Hospital of the Air Force of the Chinese People's Liberation Army, the results show that Enerxin Capsule can shorten the duration of the disease and relieve the severity of symptoms when using in the early stage after the outbreak of flu, and it is suitable for the promotion in clinical use due to its excellent safety and tolerance. The Group believes that Enerxin Capsule has a promising market prospect.

In addition, the Institute of Virology, Wuhan University (State Key Laboratory of Virology) conducted a series of Pharmacodynamics trials during the period from July 2009 to September 2009, the results showed that Enerxin Capsule had an obvious function on the restraint of the growth of Influenza A (H1N1) in cells. The function of this medicine on the block of the invasion of cells by influenza A virus is the same as that of Tamiflu. The function of Enerxin Capsule on the block of the invasion of cells by Influenza A (H1N1) is stronger than its function on the restraint of virus biosynthesis.

About Lijun International Pharmaceutical (Holding) Co., Ltd.

As one of the leading manufacturers in the pharmaceutical industry in China, Lijun International Pharmaceutical (Holding) Co., Ltd. has more than 70-year operating history and well-known brands. The Group was listed on Hong Kong Stock Exchange in December 2005 (stock code:2005). The Group is engaged in the research, development, manufacturing and selling of a wide range of finished medicines and bulk pharmaceutical products to hospitals and distributors, including antibiotics, intravenous infusion solution, non-antibiotics finished products, bulk pharmaceuticals and health care product. The Group has manufacturing plants in Hebei Province and Shaanxi Province, the People's Republic of China and sells to customers mainly in Mainland China. The Company is the largest domestic manufacturer of macrolide antibiotics, with a leading position for its intravenous infusion solution products in high-end hospital market.

The Company boasts of its robust brand strength including "Lijunsha", a "Famous Trademark" in China and one of the "Ten Favourite Trademarks" which took over approximately 66% market share in 2008. The Group successfully acquired Shijiazhuang No. 4 Pharmaceutical Co., Ltd., a leading intravenous infusion solution manufacturer in China in June 2007 to expand its intravenous infusion solution production business. Facing more merger and acquisition opportunities from medical reform, the Group is positioned for continuous mergers and acquisitions to promote its growth.

Contact

For media inquiries, please contact: Wonderful Sky Financial Group Limited Sally Wong Tel: +852-2851-1038 Fax: +852-2815-1352 Email: sallywong@wsfg.hk Daisy Sun Tel: +852-2851-1038 Fax: +852-2815-1352 Email: daisysun@wsfg.hk Long Li Tel: +852-2851-1038 Fax: +852-2815-1352 Email: lilong@wsfg.hk